1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Theracryf Plc

Theracryf Plc

TCF.L
Theracryf PlcGB flagLondon Stock Exchange
0.22
GBp
+0.00
- -
4.66MMarket Cap
Theracryf Plc
TCF.L
(London Stock Exchange)

Recent

price

0.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.01
-0.01
-0.03
-0.06
-0.04
-0.03
-0.03
-0.02
-0.02
-0.01
-0.01
-0.01
- -
Basic EPS, GAAP
-0.01
-0.01
-0.01
-0.03
-0.04
-0.03
-0.02
-0.02
-0.02
-0.01
-0.02
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.03
-0.04
-0.07
-0.13
-0.13
-0.15
-0.15
-0.13
-0.13
-0.08
-0.09
-0.1
-0.05
Book Value per Share
- -
- -
-0.02
0.14
0.06
0.05
0.02
0.03
0.08
0.03
0.02
0.01
0.01
Tangible Book Value per Share
74
74
74
51
74
80
97
131
147
275
275
275
538
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
-1,651.55
- -
-1,147.06
-898.99
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-2
-3
-3
-3
-3
-3
-3
-3
-4
-3
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
-1,378.35
- -
-914.71
-792.17
- -
Profit Margin (%)
- -
- -
- -
7
4
4
2
4
12
9
5
2
4
Working Capital
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
-1
7
4
4
2
4
12
9
5
2
6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-47.39%
43.15%
154.98%
Free Cash Flow
17.68%
2.63%
-20.99%
Net Income, GAAP
1.31%
-2.37%
-38.13%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
HAVN Life Sciences Inc. (HAVN.CN)
Genmab A/S (GMAB)
Taysha Gene Therapies, Inc. (TSHA)
IGC Pharma, Inc. (IGC)
InMed Pharmaceuticals Inc. (INM)
Beijing Tiantan Biological Products Co., Ltd. (600161.SS)
Business
Theracryf Plc (LSE:TCF) is a clinical-stage biotechnology company focused on developing innovative therapeutics for oncology and behavioral brain disorders. The company advances a diversified pipeline including its lead clinical asset SFX-01, a patented sulforaphane-based medicine in Phase II trials for metastatic breast cancer, Phase I trials for glioblastoma in collaboration with Erasmus Medical Centre, and preclinical development for rhabdomyosarcoma and neurodevelopmental disorders; orexin-1 (Ox-1) antagonist programs targeting addiction, substance use disorders, anxiety, binge eating disorder, fatigue, and narcolepsy, funded to clinical trial readiness; and additional preclinical CNS assets addressing high unmet needs in neuropsychiatry. TheraCryf licenses global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla SA, and pursues a strategy of generating data for partnering or licensing with mid- to large-sized pharmaceutical companies. Founded in 2014 and headquartered at Alderley Park, Nether Alderley, Cheshire, United Kingdom, the company operates primarily in the UK with international collaborations and targets global markets in oncology and CNS therapeutics. In April 2024, TheraCryf, formerly Evgen Pharma Plc, acquired Chronos Therapeutics Ltd, tripling its research pipeline by integrating preclinical neuropsychiatry assets and prompting a rebranding to reflect its expanded mission; in February 2025, it raised gross proceeds of £4.25 million through a conditional equity placing to advance the Ox-1 program to clinical trial readiness and extend its cash runway to end-2026; post-period, it confirmed efficacy of an improved enteric-coated SFX-01 formulation in a Phase 1b study and presented preclinical data supporting its radiosensitizing potential in glioblastoma.